Tenders Are Invited For Pharmaceutical Products – Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab

Pharmaceutical Products – Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Omalizumab. Gwq Serviceplus Ag Intends To Enter Into Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For The Above. Active Ingredient With Contract Start On October 1St, 2024. All Interested Companies Can Join This Contract At Any Time During The Contract Term Under The Same Conditions (Approval Model). The Gwq Assumes That This Procedure Does Not Fall Within The Scope Of Antitrust Procurement Law Due To The Lack Of A Selection Decision And Therefore The Non-Discriminatory Access Of All Pharmaceutical Companies. The Contract Documents, The Participating Health Insurance Companies And Their Sales As Well As The Dates For Reporting The Contract Can Be Viewed And Downloaded On The Gwq Serviceplus Ag Procurement Portal At Http://Vergabeportal.Gwq-Serviceplus.De. Until Exclusive Contracts Are Launched, This Interim Agreement Is Open To All Market Participants To Join. If The Signed Contracts/Declaration And Evidence Are Received By September 10Th, 2024, An Initial Report Can Be Made On October 1St, 2024. The Following Documents Must Be Submitted: - Signed Contract In Duplicate; - List Of Pzns That Are The Subject Of The Contract (Appendix 2); - Proof Of Drug Approval Via An Extract From The Public Part Of The Amice Database - Signed Self-Declaration (Appendix 3); - Self-Declaration On The Eu Regulation (Appendix 5) - Self-Disclosure On Sustainability (Appendix 6)